- Home
- URGN vs FBRT Comparison
URGN vs FBRT Comparison
Compare URGN & FBRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- FBRT
- Stock Information
- Founded
- URGN 2004
- FBRT 2012
- Country
- URGN United States
- FBRT United States
- Employees
- URGN N/A
- FBRT N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- FBRT Real Estate Investment Trusts
- Sector
- URGN Health Care
- FBRT Real Estate
- Exchange
- URGN Nasdaq
- FBRT Nasdaq
- Market Cap
- URGN 896.3M
- FBRT 918.2M
- IPO Year
- URGN 2017
- FBRT 1985
- Fundamental
- Price
- URGN $19.44
- FBRT $11.34
- Analyst Decision
- URGN Strong Buy
- FBRT Strong Buy
- Analyst Count
- URGN 8
- FBRT 5
- Target Price
- URGN $28.50
- FBRT $14.90
- AVG Volume (30 Days)
- URGN 1.0M
- FBRT 633.9K
- Earning Date
- URGN 08-07-2025
- FBRT 07-30-2025
- Dividend Yield
- URGN N/A
- FBRT 12.54%
- EPS Growth
- URGN N/A
- FBRT 18.52
- EPS
- URGN N/A
- FBRT 0.98
- Revenue
- URGN $94,238,000.00
- FBRT $207,768,000.00
- Revenue This Year
- URGN $39.80
- FBRT $28.21
- Revenue Next Year
- URGN $108.94
- FBRT $2.40
- P/E Ratio
- URGN N/A
- FBRT $11.55
- Revenue Growth
- URGN 10.85
- FBRT 16.05
- 52 Week Low
- URGN $3.42
- FBRT $9.79
- 52 Week High
- URGN $21.02
- FBRT $13.74
- Technical
- Relative Strength Index (RSI)
- URGN 58.49
- FBRT 63.22
- Support Level
- URGN $18.65
- FBRT $11.02
- Resistance Level
- URGN $20.11
- FBRT $11.25
- Average True Range (ATR)
- URGN 1.20
- FBRT 0.16
- MACD
- URGN -0.24
- FBRT 0.05
- Stochastic Oscillator
- URGN 60.08
- FBRT 95.31
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About FBRT Franklin BSP Realty Trust Inc.
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.